$298.12
Value $527B
ABBV and NVST stock compared: price, dividend, valuation and results, from SEC filings.
$298.12
Value $527B
$24.14
Value $4.0B
AbbVie (ABBV) has a market value of $527B and Envista (NVST) $4.0B. Over the last year, with dividends, ABBV moved +32.1% and NVST +24.4%. The P/E is 51.2 for ABBV and 6.2 for NVST. Dividend yield: ABBV 2.32%, NVST none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ABBV$527B
NVST$4.0B
ABBV is 133 times NVST
Revenue, 12 months
ABBV$66.0B
NVST$2.9B
ABBV is 23 times NVST
Net income, 12 months
ABBV$10.3B
NVST$634M
ABBV is 16 times NVST
Operating margin
ABBV32.2%
NVST25.4%
6.8 points apart
ROIC
ABBV25.7%
NVST14.8%
10.9 points apart
P/E
ABBV51.2
NVST6.2
ABBV is 8.2 times NVST
Dividend yield
ABBV2.3%
NVST0.0%
2.3 points apart
5-year return
ABBV+205.0%
NVST-43.6%
248.6 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ABBV+205.0%
NVST-43.6%
| Period | ABBVWith dividends | NVSTWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +32.1%Price +28.3% | +24.4%Price +24.4% |
| 3 years since November 16, 2023 | +138.4%+33.6% a yearPrice +115.6% | +4.5%+1.5% a yearPrice +4.5% |
| 5 years since November 15, 2021 | +205.0%+25.0% a yearPrice +155.1% | -43.6%-10.8% a yearPrice -43.6% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ABBVAbbVieNVSTEnvista
| Price | $298.12 | $24.14 |
|---|---|---|
| Market value | $527B | $4.0B |
| Enterprise value (EV) | $597B | $4.2B |
| P/E | 51.2 | 6.2 |
| P/E, 5-year median | 57.0 | 24.6 |
| P/B | – | 1.3 |
| EV/EBIT | 28.1 | 5.8 |
| Free cash flow yield | 3.6% | 6.1% |
| Revenue, 12 months | $66.0B | $2.9B |
|---|---|---|
| Net income, 12 months | $10.3B | $634M |
| Free cash flow, 12 months | $18.9B | $242M |
| Earnings per share, 12 months | $5.81 | $3.87 |
| Revenue growth, year on year | 8.6% | 8.3% |
| Revenue growth a year, past | +5.9%over 5 years | +7.1%over 5 years |
| EPS growth a year, past | -2.8%over 5 years | +7.0%over 5 years |
| Gross margin | 73.7% | 55.9% |
|---|---|---|
| Operating margin | 32.2% | 25.4% |
| Net margin | 15.7% | 22.0% |
| ROIC | 25.7% | 14.8% |
| ROE | – | 20.5% |
| Cash | $10.8B | $1.2B |
|---|---|---|
| Total debt | $80.9B | $1.6B |
| Net debt / EBITDA | 3.2 | 0.3 |
| Interest cover | 7.1× | – |
| Dividend yield | 2.3% | – |
|---|---|---|
| Dividend per share, 12 months | $6.92 | – |
| Dividend growth a year, past | +6.6%over 5 years | – |
| Buyback yield | 0.2% | 4.2% |
| Shareholder yield | 2.5% | 4.2% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, AbbVie ($527B) is about 133.2 times Envista ($4.0B), at today's prices.
Since November 15, 2021, ABBV's price moved +155.1% and NVST's -43.6%. With dividends: ABBV +205.0% (+25.0% a year), NVST -43.6% (-10.8% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.32% for AbbVie and none for Envista. Over the last twelve months they paid $6.92 and – per share.
At today's price, the P/E is 51.2 for ABBV and 6.2 for NVST. The median of the last five years was 57.0 and 24.6, which shows where each stands against its own past.
Over the last twelve months, the net margin was 15.7% for AbbVie and 22.0% for Envista, and the operating margin 32.2% and 25.4%. Revenue was $66.0B and $2.9B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.